DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks

http://www.DrugRisks.com is the most helpful resource on the web for prescription medication alerts, side effects and legal news. Visit us today.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Around 1,097 patients have filed a NuvaRing lawsuit so far alleging blood clots, with the cases consolidated to a special federal court in Missouri.

New York, NY (PRWEB) April 02, 2013

DrugRisks’ birth control resource center is announcing updated news on the site for women using the vaginal ring contraceptive NuvaRing. Recently added information shows the maker of the device, Organon, may have concealed the risk of dangerous estrogen bursts.

DrugRisks was created to improve the safety of those using popular prescription devices like NuvaRing by providing the latest warnings, recalls, studies and legal news. Visitors can determine if others are experiencing similar side effects and decide if they need legal advice.

Health experts have warned that contraceptive rings like NuvaRing may have higher risks of blood clots than traditional birth control pills. Last year, the New England Journal of Medicine published a study finding vaginal rings could relate to a 2.5 to 3-fold increased risk of blood clots*.

DrugRisks also contains information showing that FDA has received over 5,300 adverse reports for women using NuvaRing devices.** Most common among the side effects were 1,177 cases of pulmonary embolism and 1,155 reports of thrombosis or deep vein thrombosis. In more than 30% of cases, patients required hospitalization, while 3% ended in death**.

Around 1,097 patients have filed a NuvaRing lawsuit so far alleging blood clots, with the cases consolidated to a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri. U.S. District Judge Rodney Sippel, who presides over the federal cases, recently delayed the start of the first NuvaRing trial until October 21, 2013***.

Now, DrugRisk has learned that Judge Sippel entered an order on March 5th allowing patients to introduce a study by Dr. Shelley Ann Tischkau, Ph.D., which finds that NuvaRing maker Organon may have concealed the risk of estrogen bursts in test patients to the FDA, which could contribute to the blood clot risks****.

Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact DrugRisks or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of federal MDL drug injury cases, DrugRisks cautions patients to seek a lawyer with experience in this litigation, and only recommends lawyers and law firms who have already handled NuvaRing lawsuits.

Visit http://www.DrugRisks.com today for more information on the research, NuvaRing side effects and litigation news related to NuvaRing and other devices, or to speak with a lawyer.

*nejm.org/doi/full/10.1056/NEJMoa1111840
**adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING
***http://cdn.aboutlawsuits.com/wp-content/uploads/2013-03-08-NuvaRing-Order.pdf
****mo.findacase.com/research/wfrmDocViewer.aspx/xq/fac.20130305_0000431.EMO.htm/qx


Contact